Weight loss and asthma control: A systematic review of randomized controlled trials

IF 8 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Reviews Pub Date : 2025-02-12 DOI:10.1111/obr.13907

Mahdieh Abbasalizad Farhangi, George Doumat, Isis F. Baroni, Carlos A. Camargo Jr.

{"title":"Weight loss and asthma control: A systematic review of randomized controlled trials","authors":"Mahdieh Abbasalizad Farhangi, George Doumat, Isis F. Baroni, Carlos A. Camargo Jr.","doi":"10.1111/obr.13907","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>In the current systematic review and meta-analysis, we evaluated the possible role of weight loss on asthma control, quality of life (QOL), and clinical outcomes among patients with asthma.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We performed a systematic search of PubMed, CINAHL, and OVID Medline for randomized controlled human trials that examined the effects of weight loss on asthma control, QOL, and spirometry results, from 1 January 2000 to 31 December 2023. Twelve eligible studies (total n = 1052 participants) were included. Weighted mean differences (WMD) and 95% confidence intervals (CIs) were used to evaluate the effect size. Subgroup analyses and meta-regression approaches were performed to reveal possible sources of heterogeneity. Fractional polynomial modeling was performed to assess non-linear associations.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Weight loss reduced ACQ score (WMD −0.67 [95%CIs − 1.20, −0.13], P = 0.02; I<sup>2</sup> 91.3%, P < 0.001), and improved forced expiratory volume percent predicted (FEV)1<sub>pp</sub> (WMD 13.08 [95%CIs 2.42, 23.73], P = 0.02; I<sup>2</sup> 94.1%, P < 0.001) among patients with asthma. In a dose–response analysis, a significant non-linear association was reported between change in weight and changes in FEV1<sub>pp</sub> (P<sub>non-linearity</sub> = 0.01). The effects of weight loss on QOL (WMD 0.53 [−0.38, 1.44], P = 0.25; I<sup>2</sup> 95.6%, P < 0.001) and forced vital capacity percent predicted (FVC <sub>pp</sub>, WMD 4.90 [−3.22, 13.02], P = 0.24; I<sup>2</sup> 91.4%, P < 0.001) were not statistically significant.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Weight loss improves asthma control and FEV1<sub>pp</sub> among patients with asthma in a two-class meta-analysis. Because of the relatively low number of well-designed clinical trials (n = 12), further trials are needed to better define the beneficial effects of weight loss on asthma control.</p>\n </section>\n </div>","PeriodicalId":216,"journal":{"name":"Obesity Reviews","volume":"26 7","pages":""},"PeriodicalIF":8.0000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/obr.13907","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

In the current systematic review and meta-analysis, we evaluated the possible role of weight loss on asthma control, quality of life (QOL), and clinical outcomes among patients with asthma.

Methods

We performed a systematic search of PubMed, CINAHL, and OVID Medline for randomized controlled human trials that examined the effects of weight loss on asthma control, QOL, and spirometry results, from 1 January 2000 to 31 December 2023. Twelve eligible studies (total n = 1052 participants) were included. Weighted mean differences (WMD) and 95% confidence intervals (CIs) were used to evaluate the effect size. Subgroup analyses and meta-regression approaches were performed to reveal possible sources of heterogeneity. Fractional polynomial modeling was performed to assess non-linear associations.

Results

Weight loss reduced ACQ score (WMD −0.67 [95%CIs − 1.20, −0.13], P = 0.02; I² 91.3%, P < 0.001), and improved forced expiratory volume percent predicted (FEV)1_pp (WMD 13.08 [95%CIs 2.42, 23.73], P = 0.02; I² 94.1%, P < 0.001) among patients with asthma. In a dose–response analysis, a significant non-linear association was reported between change in weight and changes in FEV1_pp (P_{non-linearity} = 0.01). The effects of weight loss on QOL (WMD 0.53 [−0.38, 1.44], P = 0.25; I² 95.6%, P < 0.001) and forced vital capacity percent predicted (FVC _pp, WMD 4.90 [−3.22, 13.02], P = 0.24; I² 91.4%, P < 0.001) were not statistically significant.

Conclusion

Weight loss improves asthma control and FEV1_pp among patients with asthma in a two-class meta-analysis. Because of the relatively low number of well-designed clinical trials (n = 12), further trials are needed to better define the beneficial effects of weight loss on asthma control.

查看原文本刊更多论文

体重减轻和哮喘控制：随机对照试验的系统回顾。

背景：在当前的系统综述和荟萃分析中，我们评估了体重减轻对哮喘患者哮喘控制、生活质量（QOL）和临床结局的可能作用。方法：从2000年1月1日至2023年12月31日，我们对PubMed、CINAHL和OVID Medline进行了系统检索，以研究体重减轻对哮喘控制、生活质量和肺活量测定结果的影响的随机对照人体试验。纳入了12项符合条件的研究（共n = 1052名受试者）。采用加权平均差（WMD）和95%置信区间（ci）评价效应大小。采用亚组分析和元回归方法来揭示可能的异质性来源。采用分数多项式建模来评估非线性关联。结果：体重减轻使ACQ评分降低(WMD -0.67 [95% ci - 1.20, -0.13], P = 0.02；I2 91.3%, P pp(大规模杀伤性武器13.08 95% cis 2.42, 23.73, P = 0.02;I2 94.1%, P P P （P非线性= 0.01）。减肥对生活质量的影响(WMD = 0.53 [-0.38, 1.44], P = 0.25；I2 95.6%, P pp、大规模杀伤性武器4.90 [-3.22,13.02],P = 0.24;结论：在两类meta分析中，体重减轻可改善哮喘患者的哮喘控制和FEV1pp。由于设计良好的临床试验数量相对较少（n = 12），需要进一步的试验来更好地确定减肥对哮喘控制的有益作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Reviews 医学-内分泌学与代谢

CiteScore

19.30

自引率

1.10%

发文量

130

审稿时长

1 months

期刊介绍： Obesity Reviews is a monthly journal publishing reviews on all disciplines related to obesity and its comorbidities. This includes basic and behavioral sciences, clinical treatment and outcomes, epidemiology, prevention and public health. The journal should, therefore, appeal to all professionals with an interest in obesity and its comorbidities. Review types may include systematic narrative reviews, quantitative meta-analyses and narrative reviews but all must offer new insights, critical or novel perspectives that will enhance the state of knowledge in the field. The editorial policy is to publish high quality peer-reviewed manuscripts that provide needed new insight into all aspects of obesity and its related comorbidities while minimizing the period between submission and publication.